GAITHERSBURG, MD--(Marketwire - July 10, 2012) -
Noble Life Sciences, a provider of preclinical research services to pharmaceutical and biotechnology companies, today announced they have entered into an agreement with Auckland-based Neuren Pharmaceuticals to manage the development of their antibody-based oncology drugs.
Alain Cappeluti, President of Noble Life Sciences, stated, "We are excited to collaborate with Perseis and Neuren to manage their oncology program. This partnership will benefit from Noble's core strengths in assisting companies with their drug development programs."
Noble's services provided under the agreement include cell line development; performing preclinical efficacy studies; manufacture of the therapeutic; and designing and overseeing IND enabling and clinical studies. The Noble team will also design and execute a plan for biomarker discovery and validation to support clinical development of the lead therapeutic antibodies.
Larry Glass, CEO of Neuren Pharmaceuticals, stated, "We were impressed with the expertise and experience of the Noble scientific team. We look forward to partnering with them as we develop our monoclonal antibody therapeutic targeted at trefoil factors (TFF-1 and TFF-3). Trefoil factors play a significant role in the growth and spread of breast cancer as well as response to treatment."
About Noble Life Sciences
Noble Life Sciences provides in vitro and in vivo preclinical research services including experimental design and testing, disease models, selection and validation of biomarkers for personalized medicine, and vivarium services. With deep expertise in preclinical drug development, the company offers access to their top scientists who work collaboratively with researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions to expedite preclinical research and guide clinical development. For more information about Noble Life Sciences, visit www.noblelifesci.com.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson's and Alzheimer's diseases. Through its Perseis Therapeutics subsidiary, Neuren is engaged in research and development of cancer therapies related to the functions of growth factors. Neuren has operations in New Zealand (Auckland-based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU). For more information, visit www.neurenpharma.com.